CACaption Management, LLC
Institutional investor · Portfolio as of Q3 2023
Top Holdings1,240 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ACTIVISION BLIZZARD INC | 1.8M | $171.7M | 2.6% | — | — | — | Decreased — |
HORIZON THERAPEUTICS PLC | 1.1M | $132.3M | 2.0% | — | — | — | Decreased — |
SEAGEN INC | 598,500 | $127M | 2.0% | — | — | — | Increased — |
T-MOBILE US INC | 590,000 | $82.6M | 1.3% | — | — | — | Increased — |
AVI BIOPHARMA INC | 656,100 | $79.5M | 1.2% | — | — | — | Increased — |
T-MOBILE US INC | 530,000 | $74.2M | 1.1% | — | — | — | New — |
CITIGROUP INC | 1.7M | $71M | 1.1% | $37.52 | 0.00% | 1 qtr | New 68 |
PALO ALTO NETWORKS INC | 302,400 | $70.9M | 1.1% | — | — | — | Decreased — |
CITIGROUP INC | 1.7M | $69.9M | 1.1% | — | — | — | New — |
ARGENX SE - ADR | 124,500 | $61.2M | 0.9% | — | — | — | Increased — |
ISHARES TR | 775,000 | $60.8M | 0.9% | — | — | — | Unchanged — |
ALPHABET INC-CL C | 430,000 | $56.7M | 0.9% | — | — | — | Unchanged — |
| 2.2M | $55.2M | 0.9% | — | — | — | Decreased — | |
HORIZON THERAPEUTICS PLC | 460,200 | $53.2M | 0.8% | — | — | — | Decreased — |
AVI BIOPHARMA INC | 396,500 | $48.1M | 0.7% | — | — | — | Increased — |
AMERISOURCEBERGEN CORP | 264,400 | $47.6M | 0.7% | — | — | — | New — |
SPDR SERIES TRUST | 1.1M | $46.8M | 0.7% | $39.19 | 0.00% | 1 qtr | New 57 |
KENVUE INC | 2.3M | $46.7M | 0.7% | — | — | — | New — |
SPDR SERIES TRUST | 1.1M | $45.9M | 0.7% | — | — | — | New — |
RH | 173,700 | $45.9M | 0.7% | — | — | — | New — |
Caption Management, LLC manages $6.5B across 1240 positions as of Q3 2023. Top holdings: ATVI (2.6%), HZNP (2.0%), SGEN (2.0%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 1/5.0.
Active quarter - 208 new positions, 141 exits, 81 increased. Top move: C (NEW, conviction 68). Portfolio: $6.5B across 1240 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer